The present state of the tuberculosis drug development pipeline

Current Opinion in Pharmacology

Volumn 42, Issue , 2018, Pages 81-94

  J Libardo, M Daben ^a   Boshoff, Helena IM ^a   Barry, Clifton E ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; BENZOXABOROLE DERIVATIVE; BRD 4592; BTZ 043; CLOFAZIMINE; DELAMANID; DELPAZOLID; DG 70; GSK 656; IMBI 3; LEVOFLOXACIN; MACOZINONE; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; NITAZOXANIDE; OPC 167832; PLACEBO; POSIZOLID; PRETOMANID; RIFAMPICIN; SORAFENIB; SPECTINAMIDE 1810; SUTEZOLID; TAM 16; TBA 7371; TBAJ 587; TELACEBEC; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; V 13 011503; V 13 012725;

ANTIBACTERIAL ACTIVITY; BACTERICIDAL ACTIVITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG METABOLISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; IC50; LUNG GRANULOMA; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; MULTIPLE DRUG DOSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

EID: 85051800113     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2018.08.001     Document Type: Review

References (72)

1. Collaborators GBDT, The global burden of tuberculosis: results from the Global Burden of Disease Study 2015. Lancet Infect Dis 18 (2018), 261–284.
2. Mitchison, D.A., The diagnosis and therapy of tuberculosis during the past 100 years. Am J Respir Crit Care Med 171 (2005), 699–706.
3. Aggarwal, A., Parai, M.K., Shetty, N., Wallis, D., Woolhiser, L., Hastings, C., Dutta, N.K., Galaviz, S., Dhakal, R.C., Shrestha, R., et al. Development of a Novel Lead that Targets M. tuberculosis polyketide Synthase 13. Cell 170 (2017), 249–259 e225 This report reinforces the utility of whole-genome sequencing of resistant mutants for target identification coupled with structure-guided drug design in the transition between lead molecules and drugs.
4. Li, X., Hernandez, V., Rock, F.L., Choi, W., Mak, Y.S.L., Mohan, M., Mao, W., Zhou, Y., Easom, E.E., Plattner, J.J., et al. Discovery of a potent and specific M. tuberculosis Leucyl-tRNA synthetase inhibitor: (S)-3-(aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2]oxaborol-1(3H)-ol (GSK656). J Med Chem 60 (2017), 8011–8026.
5. Palencia, A., Li, X., Bu, W., Choi, W., Ding, C.Z., Easom, E.E., Feng, L., Hernandez, V., Houston, P., Liu, L., et al. Discovery of novel oral protein synthesis inhibitors of M. tuberculosis that target leucyl-tRNA synthetase. Antimicrob Agents Chemother 60 (2016), 6271–6280.
6. Lee, W., VanderVen, B.C., Fahey, R.J., Russell, D.G., Intracellular Mycobacterium tuberculosis exploits host-derived fatty acids to limit metabolic stress. J Biol Chem 288 (2013), 6788–6800.
7. Kasbekar, M., Fischer, G., Mott, B.T., Yasgar, A., Hyvonen, M., Boshoff, H.I., Abell, C., Barry, C.E. 3rd, Thomas, C.J., Selective small molecule inhibitor of the Mycobacterium tuberculosis fumarate hydratase reveals an allosteric regulatory site. Proc Natl Acad Sci U S A 113 (2016), 7503–7508.
8. Liu, Y., Zhou, S., Deng, Q., Li, X., Meng, J., Guan, Y., Li, C., Xiao, C., Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis. Tuberculosis (Edinb) 97 (2016), 38–46.
9. Huang, H.L., Krieger, I.V., Parai, M.K., Gawandi, V.B., Sacchettini, J.C., Mycobacterium tuberculosis malate synthase structures with fragments reveal a portal for substrate/product exchange. J Biol Chem 291 (2016), 27421–27432.
10. Krieger, I.V., Freundlich, J.S., Gawandi, V.B., Roberts, J.P., Gawandi, V.B., Sun, Q., Owen, J.L., Fraile, M.T., Huss, S.I., Lavandera, J.L., et al. Structure-guided discovery of phenyl-diketo acids as potent inhibitors of M. tuberculosis malate synthase. Chem Biol 19 (2012), 1556–1567.
11. Pandey, A.K., Sassetti, C.M., Mycobacterial persistence requires the utilization of host cholesterol. Proc Natl Acad Sci U S A 105 (2008), 4376–4380.
12. VanderVen, B.C., Fahey, R.J., Lee, W., Liu, Y., Abramovitch, R.B., Memmott, C., Crowe, A.M., Eltis, L.D., Perola, E., Deininger, D.D., et al. Novel inhibitors of cholesterol degradation in Mycobacterium tuberculosis reveal how the bacterium's metabolism is constrained by the intracellular environment. PLoS Pathog, 11, 2015, e1004679.
13. Christophe, T., Jackson, M., Jeon, H.K., Fenistein, D., Contreras-Dominguez, M., Kim, J., Genovesio, A., Carralot, J.P., Ewann, F., Kim, E.H., et al. High content screening identifies decaprenyl-phosphoribose 2’ epimerase as a target for intracellular antimycobacterial inhibitors. PLoS Pathog, 5, 2009, e1000645.
14. Silva-Miranda, M., Ekaza, E., Breiman, A., Asehnoune, K., Barros-Aguirre, D., Pethe, K., Ewann, F., Brodin, P., Ballell-Pages, L., Altare, F., High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis. Antimicrob Agents Chemother 59 (2015), 693–697.
15. Puissegur, M.P., Botanch, C., Duteyrat, J.L., Delsol, G., Caratero, C., Altare, F., An in vitro dual model of mycobacterial granulomas to investigate the molecular interactions between mycobacteria and human host cells. Cell Microbiol 6 (2004), 423–433.
16. Abrahams, K.A., Cox, J.A.G., Futterer, K., Rullas, J., Ortega-Muro, F., Loman, N.J., Moynihan, P.J., Perez-Herran, E., Jimenez, E., Esquivias, J., et al. Inhibiting mycobacterial tryptophan synthase by targeting the inter-subunit interface. Sci Rep, 7, 2017, 9430.
17. Wellington, S., Nag, P.P., Michalska, K., Johnston, S.E., Jedrzejczak, R.P., Kaushik, V.K., Clatworthy, A.E., Siddiqi, N., McCarren, P., Bajrami, B., et al. A small-molecule allosteric inhibitor of Mycobacterium tuberculosis tryptophan synthase. Nat Chem Biol 13 (2017), 943–950 This paper describes the inhibition of a highly dynamic, multi-subunit metabolic enzyme within vivo essentiality via uncompetitive mechanisms using a small molecule that binds to an allosteric site. This paper opened up a new paradigm in the design of next-generation antimicrobials that don't necessarily bind to the active site.
18. Brunner, K., Maric, S., Reshma, R.S., Almqvist, H., Seashore-Ludlow, B., Gustavsson, A.L., Poyraz, O., Yogeeswari, P., Lundback, T., Vallin, M., et al. Inhibitors of the cysteine synthase CysM with antibacterial potency against dormant Mycobacterium tuberculosis. J Med Chem 59 (2016), 6848–6859.
19. Mishra, A., Mamidi, A.S., Rajmani, R.S., Ray, A., Roy, R., Surolia, A., An allosteric inhibitor of Mycobacterium tuberculosis ArgJ: implications to a novel combinatorial therapy. EMBO Mol Med, 2018.
20. Zhang, Y.J., Reddy, M.C., Ioerger, T.R., Rothchild, A.C., Dartois, V., Schuster, B.M., Trauner, A., Wallis, D., Galaviz, S., Huttenhower, C., et al. Tryptophan biosynthesis protects mycobacteria from CD4 T-cell-mediated killing. Cell 155 (2013), 1296–1308.
21. Park, Y., Pacitto, A., Bayliss, T., Cleghorn, L.A., Wang, Z., Hartman, T., Arora, K., Ioerger, T.R., Sacchettini, J., Rizzi, M., et al. Essential but not vulnerable: indazole sulfonamides targeting inosine monophosphate dehydrogenase as potential leads against Mycobacterium tuberculosis. ACS Infect Dis 3 (2017), 18–33 This paper argues that while inhibition of essential enzymes should intuitively lead toin vivo efficacy, levels of bioavailable metabolites can rescue bacterial growth and render the drug inactive. Hence, drug discovery efforts should not bias against non-essential targets.
22. Trapero, A., Pacitto, A., Singh, V., Sabbah, M., Coyne, A.G., Mizrahi, V., Blundell, T.L., Ascher, D.B., Abell, C., Fragment-based approach to targeting inosine-5’-monophosphate dehydrogenase (IMPDH) from Mycobacterium tuberculosis. J Med Chem, 2018.
23. Sukheja, P., Kumar, P., Mittal, N., Li, S.G., Singleton, E., Russo, R., Perryman, A.L., Shrestha, R., Awasthi, D., Husain, S., et al. A novel small-molecule inhibitor of the Mycobacterium tuberculosis demethylmenaquinone methyltransferase MenG is bactericidal to both growing and nutritionally deprived persister cells. MBio, 8, 2017.
24. Hong, W.D., Gibbons, P.D., Leung, S.C., Amewu, R., Stocks, P.A., Stachulski, A., Horta, P., Cristiano, M.L.S., Shone, A.E., Moss, D., et al. Rational design, synthesis, and biological evaluation of heterocyclic quinolones targeting the respiratory chain of Mycobacterium tuberculosis. J Med Chem 60 (2017), 3703–3726.
25. Tantry, S.J., Markad, S.D., Shinde, V., Bhat, J., Balakrishnan, G., Gupta, A.K., Ambady, A., Raichurkar, A., Kedari, C., Sharma, S., et al. Discovery of imidazo[1,2-a]pyridine ethers and squaramides as selective and potent inhibitors of mycobacterial adenosine triphosphate (ATP) synthesis. J Med Chem 60 (2017), 1379–1399.
26. Naran, K., Moosa, A., Barry, C.E. 3rd, Boshoff, H.I., Mizrahi, V., Warner, D.F., Bioluminescent reporters for rapid mechanism of action assessment in tuberculosis drug discovery. Antimicrob Agents Chemother 60 (2016), 6748–6757 This paper reported twoM. tuberculosis strains that can be used to rapidly triage hits from whole-cell screening to filter out cell wall biosynthesis inhibitors and DNA damaging agents avoiding the identification of redundant targets downstream of the MOA studies.
27. Arora, K., Ochoa-Montano, B., Tsang, P.S., Blundell, T.L., Dawes, S.S., Mizrahi, V., Bayliss, T., Mackenzie, C.J., Cleghorn, L.A., Ray, P.C., et al. Respiratory flexibility in response to inhibition of cytochrome C oxidase in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58 (2014), 6962–6965.
28. Choi, P.J., Sutherland, H.S., Tong, A.S.T., Blaser, A., Franzblau, S.G., Cooper, C.B., Lotlikar, M.U., Upton, A.M., Guillemont, J., Motte, M., et al. Synthesis and evaluation of analogues of the tuberculosis drug bedaquiline containing heterocyclic B-ring units. Bioorg Med Chem Lett 27 (2017), 5190–5196.
29. Sutherland, H.S., Tong, A.S.T., Choi, P.J., Conole, D., Blaser, A., Franzblau, S.G., Cooper, C.B., Upton, A.M., Lotlikar, M.U., Denny, W.A., et al. Structure–activity relationships for analogs of the tuberculosis drug bedaquiline with the naphthalene unit replaced by bicyclic heterocycles. Bioorg Med Chem, 2018.
30. Liu, J., Bruhn, D.F., Lee, R.B., Zheng, Z., Janusic, T., Scherbakov, D., Scherman, M.S., Boshoff, H.I., Das, S., Rakesh, et al. Structure–activity relationships of spectinamide antituberculosis agents: a dissection of ribosomal inhibition and native efflux avoidance contributions. ACS Infect Dis 3 (2017), 72–88.
31. Madhura, D.B., Liu, J., Meibohm, B., Lee, R.E., Phase II metabolic pathways of spectinamide antitubercular agents: a comparative study of the reactivity of 4-substituted pyridines to glutathione conjugation. MedChemComm 7 (2016), 114–117.
32. Foo, C.S., Lechartier, B., Kolly, G.S., Boy-Rottger, S., Neres, J., Rybniker, J., Lupien, A., Sala, C., Piton, J., Cole, S.T., Characterization of DprE1-mediated benzothiazinone resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother 60 (2016), 6451–6459.
33. Makarov, V., Manina, G., Mikusova, K., Mollmann, U., Ryabova, O., Saint-Joanis, B., Dhar, N., Pasca, M.R., Buroni, S., Lucarelli, A.P., et al. Benzothiazinones kill Mycobacterium tuberculosis by blocking Arabinan synthesis. Science 324 (2009), 801–804.
34. Kloss, F., Krchnak, V., Krchnakova, A., Schieferdecker, S., Dreisbach, J., Krone, V., Mollmann, U., Hoelscher, M., Miller, M.J., In vivo dearomatization of the potent antituberculosis agent BTZ043 via meisenheimer complex formation. Angew Chem Int Ed Engl 56 (2017), 2187–2191.
35. Pethe, K., Bifani, P., Jang, J., Kang, S., Park, S., Ahn, S., Jiricek, J., Jung, J., Jeon, H.K., Cechetto, J., et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med 19 (2013), 1157–1160.
36. Diacon, A.H., Donald, P.R., The early bactericidal activity of antituberculosis drugs. Expert Rev Anti Infect Ther 12 (2014), 223–237.
37. Jindani, A., Dore, C.J., Mitchison, D.A., Bactericidal and sterilizing activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 167 (2003), 1348–1354.
38. Tahlan, K., Wilson, R., Kastrinsky, D.B., Arora, K., Nair, V., Fischer, E., Barnes, S.W., Walker, J.R., Alland, D., Barry, C.E. 3rd, et al. SQ109 targets MmpL3, a membrane transporter of trehalose monomycolate involved in mycolic acid donation to the cell wall core of Mycobacterium tuberculosis. Antimicrob Agents Chemother 56 (2012), 1797–1809.
39. Heinrich, N., Dawson, R., du Bois, J., Narunsky, K., Horwith, G., Phipps, A.J., Nacy, C.A., Aarnoutse, R.E., Boeree, M.J., Gillespie, S.H., et al. Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients. J Antimicrob Chemother 70 (2015), 1558–1566.
40. Boeree, M.J., Heinrich, N., Aarnoutse, R., Diacon, A.H., Dawson, R., Rehal, S., Kibiki, G.S., Churchyard, G., Sanne, I., Ntinginya, N.E., et al. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial. Lancet Infect Dis 17 (2017), 39–49 This study demonstrated that a multi-arm, multi-stage trial can greatly speed-up the development of drug regimens in advanced phases of clinical trials. This concept is particularly useful in multicenter, high-burden tuberculosis study sites.
41. Nikonenko, B.V., Protopopova, M., Samala, R., Einck, L., Nacy, C.A., Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrob Agents Chemother 51 (2007), 1563–1565.
42. Xu, Z., Meshcheryakov, V.A., Poce, G., Chng, S.S., MmpL3 is the flippase for mycolic acids in mycobacteria. Proc Natl Acad Sci U S A 114 (2017), 7993–7998.
43. Li, W., Upadhyay, A., Fontes, F.L., North, E.J., Wang, Y., Crans, D.C., Grzegorzewicz, A.E., Jones, V., Franzblau, S.G., Lee, R.E., et al. Novel insights into the mechanism of inhibition of MmpL3, a target of multiple pharmacophores in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58 (2014), 6413–6423.
44. Wallis, R.S., Dawson, R., Friedrich, S.O., Venter, A., Paige, D., Zhu, T., Silvia, A., Gobey, J., Ellery, C., Zhang, Y., et al. Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis. PLoS ONE, 9, 2014, e94462.
45. Furin, J.J., Du Bois, J., van Brakel, E., Chheng, P., Venter, A., Peloquin, C.A., Alsultan, A., Thiel, B.A., Debanne, S.M., Boom, W.H., et al. Early bactericidal activity of AZD5847 in patients with pulmonary tuberculosis. Antimicrob Agents Chemother 60 (2016), 6591–6599.
46. Jindani, A., Harrison, T.S., Nunn, A.J., Phillips, P.P., Churchyard, G.J., Charalambous, S., Hatherill, M., Geldenhuys, H., McIlleron, H.M., Zvada, S.P., et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 371 (2014), 1599–1608.
47. Merle, C.S., Fielding, K., Sow, O.B., Gninafon, M., Lo, M.B., Mthiyane, T., Odhiambo, J., Amukoye, E., Bah, B., Kassa, F., et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 371 (2014), 1588–1598.
48. Gillespie, S.H., Crook, A.M., McHugh, T.D., Mendel, C.M., Meredith, S.K., Murray, S.R., Pappas, F., Phillips, P.P., Nunn, A.J., Consortium, R.E., Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 371 (2014), 1577–1587.
49. Bouton, T.C., Phillips, P.P.J., Mitnick, C.D., Peloquin, C.A., Eisenach, K., Patientia, R.F., Lecca, L., Gotuzzo, E., Gandhi, N.R., Butler, D., et al. An optimized background regimen design to evaluate the contribution of levofloxacin to multidrug-resistant tuberculosis treatment regimens: study protocol for a randomized controlled trial. Trials, 18, 2017, 563.
50. Murray, S., Mendel, C., Spigelman, M., TB alliance regimen development for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 20 (2016), 38–41.
51. Shigyo, K., Ocheretina, O., Merveille, Y.M., Johnson, W.D., Pape, J.W., Nathan, C.F., Fitzgerald, D.W., Efficacy of nitazoxanide against clinical isolates of Mycobacterium tuberculosis. Antimicrob Agents Chemother 57 (2013), 2834–2837.
52. Tasneen, R., Li, S.Y., Peloquin, C.A., Taylor, D., Williams, K.N., Andries, K., Mdluli, K.E., Nuermberger, E.L., Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother 55 (2011), 5485–5492.
53. Diacon, A.H., Dawson, R., von Groote-Bidlingmaier, F., Symons, G., Venter, A., Donald, P.R., van Niekerk, C., Everitt, D., Winter, H., Becker, P., et al. 14-day bactericidal activity of PA-824, bedaquiline, pyrazinamide, and moxifloxacin combinations: a randomised trial. Lancet 380 (2012), 986–993.
54. Dawson, R., Diacon, A.H., Everitt, D., van Niekerk, C., Donald, P.R., Burger, D.A., Schall, R., Spigelman, M., Conradie, A., Eisenach, K., et al. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet 385 (2015), 1738–1747.
55. Moodley, R., Godec, T.R., Team, S.T., Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials. Eur Respir Rev 25 (2016), 29–35.
56. Lenaerts, A., Barry, C.E. 3rd, Dartois, V., Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses. Immunol Rev 264 (2015), 288–307.
57. Via, L.E., England, K., Weiner, D.M., Schimel, D., Zimmerman, M.D., Dayao, E., Chen, R.Y., Dodd, L.E., Richardson, M., Robbins, K.K., et al. A sterilizing tuberculosis treatment regimen is associated with faster clearance of bacteria in cavitary lesions in marmosets. Antimicrob Agents Chemother 59 (2015), 4181–4189.
58. Ramakrishnan, L., Revisiting the role of the granuloma in tuberculosis. Nat Rev Immunol 12 (2012), 352–366.
59. Russell, D.G., Cardona, P.J., Kim, M.J., Allain, S., Altare, F., Foamy macrophages and the progression of the human tuberculosis granuloma. Nat Immunol 10 (2009), 943–948.
60. Barry, C.E. 3rd, Boshoff, H.I., Dartois, V., Dick, T., Ehrt, S., Flynn, J., Schnappinger, D., Wilkinson, R.J., Young, D., The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat Rev Microbiol 7 (2009), 845–855.
61. Srivastava, S., Pasipanodya, J.G., Meek, C., Leff, R., Gumbo, T., Multidrug-resistant tuberculosis not due to noncompliance but to between-patient pharmacokinetic variability. J Infect Dis 204 (2011), 1951–1959.
62. Prideaux, B., Via, L.E., Zimmerman, M.D., Eum, S., Sarathy, J., O'Brien, P., Chen, C., Kaya, F., Weiner, D.M., Chen, P.Y., et al. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat Med 21 (2015), 1223–1227.
63. DeMarco, V.P., Ordonez, A.A., Klunk, M., Prideaux, B., Wang, H., Zhuo, Z., Tonge, P.J., Dannals, R.F., Holt, D.P., Lee, C.K., et al. Determination of [11C]rifampin pharmacokinetics within Mycobacterium tuberculosis-infected mice by using dynamic positron emission tomography bioimaging. Antimicrob Agents Chemother 59 (2015), 5768–5774.
64. Sarathy, J.P., Via, L.E., Weiner, D., Blanc, L., Boshoff, H., Eugenin, E.A., Barry, C.E. 3rd, Dartois, V.A., Extreme drug tolerance of Mycobacterium tuberculosis in caseum. Antimicrob Agents Chemother, 62, 2018 This study describes the development of anex vivo drug susceptibility testing against M. tuberculosis in their most clinically relevant setting — the cavity caseum. This paper also demonstrated that bacilli within the caseum are indeed nonreplicating.
65. Lanoix, J.P., Ioerger, T., Ormond, A., Kaya, F., Sacchettini, J., Dartois, V., Nuermberger, E., Selective inactivity of pyrazinamide against tuberculosis in C3HeB/FeJ mice is best explained by neutral pH of caseum. Antimicrob Agents Chemother 60 (2016), 735–743.
66. Zimmerman, M., Lestner, J., Prideaux, B., O'Brien, P., Dias-Freedman, I., Chen, C., Dietzold, J., Daudelin, I., Kaya, F., Blanc, L., et al. Ethambutol Partitioning in Tuberculous Pulmonary Lesions Explains Its Clinical Efficacy. Antimicrob Agents Chemother, 61, 2017.
67. Irwin, S.M., Prideaux, B., Lyon, E.R., Zimmerman, M.D., Brooks, E.J., Schrupp, C.A., Chen, C., Reichlen, M.J., Asay, B.C., Voskuil, M.I., et al. Bedaquiline and pyrazinamide treatment responses are affected by pulmonary lesion heterogeneity in Mycobacterium tuberculosis infected C3HeB/FeJ mice. ACS Infect Dis 2 (2016), 251–267 This study uncovered key pharmacokinetic parameters, including caseum drug distribution, that may impact the course of treatment.
68. Rifat, D., Prideaux, B., Savic, R.M., Urbanowski, M.E., Parsons, T.L., Luna, B., Marzinke, M.A., Ordonez, A.A., DeMarco, V.P., Jain, S.K., et al. Pharmacokinetics of rifapentine and rifampin in a rabbit model of tuberculosis and correlation with clinical trial data. Sci Transl Med, 10, 2018.
69. Savic, R.M., Weiner, M., MacKenzie, W.R., Engle, M., Whitworth, W.C., Johnson, J.L., Nsubuga, P., Nahid, P., Nguyen, N.V., Peloquin, C.A., et al. Defining the optimal dose of rifapentine for pulmonary tuberculosis: exposure-response relations from two phase II clinical trials. Clin Pharmacol Ther 102 (2017), 321–331.
70. Pienaar, E., Sarathy, J., Prideaux, B., Dietzold, J., Dartois, V., Kirschner, D.E., Linderman, J.J., Comparing efficacies of moxifloxacin, levofloxacin and gatifloxacin in tuberculosis granulomas using a multi-scale systems pharmacology approach. PLoS Comput Biol, 13, 2017, e1005650.
71. Sarathy, J.P., Liang, H.H., Weiner, D., Gonzales, J., Via, L.E., Dartois, V., An in vitro caseum binding assay that predicts drug penetration in tuberculosis lesions. J Vis Exp, 2017.
72. Sarathy, J.P., Zuccotto, F., Hsinpin, H., Sandberg, L., Via, L.E., Marriner, G.A., Masquelin, T., Wyatt, P., Ray, P., Dartois, V., Prediction of drug penetration in tuberculosis lesions. ACS Infect Dis 2 (2016), 552–563 This is the first report of semi-empirical rules that predict the caseum distribution potential of a lead molecule based solely on its structure.